Covishield's first dose develops strong immunity than Covaxin's: ICMR head
India | May 21, 2021, 12:40 PM ISTThe Covid-19 Working Group based on the available real-life evidence suggested that the interval should be extended to 12-16 weeks.
The Covid-19 Working Group based on the available real-life evidence suggested that the interval should be extended to 12-16 weeks.
External Affairs Minister S Jaishankar will visit the US in the coming week from May 24 to May 28. The official announcement was made by Ministry of External Affairs on Friday.
About 150 Covid vaccination sites have been shut in Delhi from today due to shortage of vaccine.
BJP president JP Nadda said that coronavirus vaccine will be available for all in the country by December.
There are two vaccine makers in the country currently -- Bharat Biotech and Serum Institute of India -- which are manufacturing Covaxin and Covishield, respectively. Only three vaccines have so far been approved to be sold in India --- Covaxin, Coveshield and Sputnik V.
Serum Institute of India (SII) CEO Adar Poonawalla said that vaccination in a large populous country such as India won't be possible in 2-3 months.
According to the scientist, vaccine doses will be safe no matter when they are taken but will not provide any great "boosting" if given within less than a month or so of the previous dose.
WHO chief Tedros Adhanom Ghebreyesus has said that once the devastating COVID-19 outbreak in India recedes, the Serum Institute of India will need to “get back on track and catch up” on its delivery commitments to COVAX, the global initiative to supply coronavirus vaccines to nations around the world.
AAP MLA Atishi Marlena on Monday said that the national capital was running out of vaccine stock. Raising an alarm, Atishi claimed that Delhi has less than a day's stock of Covaxin for 45-plus after Monday evening while Covisheild will last only for five days.
Alerts have been raised in some countries on post-vaccination "embolic and thrombotic events" on 11 March, 2021 particularly with AstraZeneca-Oxford vaccine (Covishield in India).
The first batch of anti-COVID drug 2-DG, developed by the DRDO, will be released on Monday (May 17) by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan, officials said.
Requisite changes have now been made on the CoWIN digital portal, making online or on-site appointments for Covishield vaccine not possible if the period after first dose for a beneficiary is less than 84 days, it was announced on Sunday.
The Union health ministry on Sunday clarified that already booked online appointments for second dose of Covishield vaccine will remain valid and the same will not be cancelled on Co-WIN platform.
The cumulative number of COVID-19 vaccine doses administered in the country is nearly 18 crore. India is the fastest country globally to reach the 17 crore target in 114 days.
Delhi Health Minister also urged the Centre to share Bharat Biotech's Covaxin formula with other companies to prevent a shortage.
The IIT Alumni Council-founded Megalab has secured a Rs 300-crore seed funding and is developing a two-dose Ayurveda-based coronavirus vaccin.
A total of 1.47 crore people have been vaccinated against COVID-19 in Gujarat so far. While 1.09 crore people have received the first dose, 37.89 lakh others were administered the second dose.
Gurugram administration will organise a day-long 'drive-in vaccination' programme to administer the second dose of Covishield to the 45+ age group at the DLF City Centre Mall on Friday.
The present gap between the two doses of Covishield vaccine is 6-8 weeks.
The Maharashtra state cabinet held a meeting on Wednesday to discuss the Covid management.
Top News
Latest News